Analyst Ratings For Intra-Cellular Therapies
Analyst Ratings For Intra-Cellular Therapies
分析师对细胞内疗法的评级
Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse set of opinions from bullish to bearish.
在过去的三个月中，有18位分析师对细胞内疗法（纳斯达克股票代码：ITCI）进行了评估，提供了从看涨到看跌的不同观点。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表简要概述了他们最近的评级，重点介绍了过去30天中情绪的变化，并将其与前几个月进行了比较。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.94, a high estimate of $120.00, and a low estimate of $77.00. Marking an increase of 11.44%, the current average surpasses the previous average price target of $82.50.
分析师通过对12个月目标股价的评估提供了更深入的见解，显示平均目标价为91.94美元，最高估计为120.00美元，低估值为77.00美元。当前的平均价格上涨了11.44％，超过了之前的平均目标股价82.50美元。
Diving into Analyst Ratings: An In-Depth Exploration
深入分析师评级：深度探索
An in-depth analysis...
对分析师...
登录免费看全文
登录/注册